Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Tocilizumab
Treatment for COVID-19
Typical Dosage: 8 mg/kg IV (max 800 mg)
Effectiveness
80%
Safety Score
45%
Clinical Trials
86
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
8 mg/kg IV (max 800 mg)
Time to Effect
2-5 days
Treatment Duration
Single dose or two doses
Evidence Quality
HIGHNumber Needed to Treat (NNT)
28(Treat 28 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$100
Side Effect Mgmt:$200
Total Annual:$1,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$12,000/QALY
QALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$2,769.23
Comparison vs Dexamethasone
Cost Difference
+$1,500/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Tocilizumab Outcomes
for COVID-19
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+65%
Common Side Effects
Serious infections
+8%
Neutropenia
+7%
Elevated liver enzymes
+6%
GI perforation
+0.5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
9 completed trials for Tocilizumab in COVID-19
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
NCT04363736COMPLETEDPHASE2
97 participants
INTERVENTIONAL
Phoenix, United States +23 more
Started: May 5, 2020
Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
NCT04331795COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Chicago, United States
Started: Apr 4, 2020
Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia
NCT04445272COMPLETEDPHASE2
495 participants
INTERVENTIONAL
Palma de Mallorca, Spain +41 more
Started: May 22, 2020
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
NCT04730323COMPLETEDPHASE4
93 participants
INTERVENTIONAL
Lahore, Pakistan
Started: May 12, 2020
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
NCT05164133COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Los Angeles, United States +24 more
Started: Jun 10, 2022
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
NCT05082714COMPLETEDNA
251 participants
INTERVENTIONAL
Pátrai, Greece
Started: Oct 20, 2021
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
NCT04678739COMPLETEDPHASE3
205 participants
INTERVENTIONAL
Chittagong, Bangladesh +3 more
Started: Aug 15, 2020
The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
NCT05035589COMPLETED
100 participants
OBSERVATIONAL
Msida, Malta
Started: Sep 20, 2021
Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study
NCT04893031COMPLETED
213 participants
OBSERVATIONAL
Trabzon, Turkey (Türkiye)
Started: Mar 1, 2020
Showing 20 of 86 total trials